TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors

Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors

Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in routine clinical practice (octreoscan ® ; multiphase SPECT / CT, MRI or endoscopy).

Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy octreoscan ®, with a potential impact on the therapeutic management of patients.

Inclusion Criteria:

• Age over 18 years
• effective contraception or exclusion of pregnancy dosage of beta-HCG in women of childbearing age
• Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional imaging (multiphase CT; MRI, US endoscopy) associated or not associated with clinical or biological signs of TE-GEP tumors (increase in tumor markers) OR
• Histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the initial staging OR
• Suspicion of recurrence or progression of well differentiated TE-GEP tumors on conventional imaging or laboratory tests (increase in tumor markers) OR
• Clinical or biological syndrome strongly suggestive of digestive endocrine disease without identification of lesions with conventional imaging
• Informed consent and patient's written
• Affiliation to an insurance

Exclusion Criteria:

• Multiple endocrine neoplasia
• TE GEP tumor not differentiated
• Pregnancy and lactation
• Persons protected by law
• Restlessness, inability to lie still hold at least 1 hour; Claustrophobia
• Poor compliance predictable or inability to undergo medical test for geographical, social or psychological
• Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks of previous morphological and scintigraphic examinations. In case of treatment with somatostatin analogues delayed, scans will be performed 4 weeks after the last injection. However, a shorter period may be observed to avoid to do again the initial assessment exams.
• malignancy except basal cell cancers and cancer in situ of the cervix
• Contraindication of injection of a contrast agent necessary for the production of multiphase scanner.
• Patients who had a CT scan without injection of contrast material can not participate in the study